Advertisement
News
Subscribe to MDT Magazine News

FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors

May 6, 2011 6:42 am | by Bio-Medicine.Org | Comments

MANHATTAN BEACH, Calif., May 6, 2011 /- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all...

TOPICS:

InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference

May 6, 2011 6:41 am | by Bio-Medicine.Org | Comments

TEL AVIV, Israel, May 6, 2011 /- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, today announced that Mr. Ofir Paz, InspireMD's co-founder and chief executive officer, and Mr. Craig Shore, chief financial...

TOPICS:

Alexza to Present at the MDB Bright Lights Conference 2011

May 6, 2011 6:40 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., May 6, 2011 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the MDB Bright Lights Conference 2011.  The Alexza presentation will be on Tuesday,...

TOPICS:
Advertisement

CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation

May 6, 2011 6:40 am | by Bio-Medicine.Org | Comments

ATLANTA and IRVINE, Calif., May 6, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the final results of its tender offer, including proration results, through its wholly owned subsidiary CL Falcon,...

TOPICS:

BC scientists link to European Consortium studying human genome

May 6, 2011 3:56 am | by EurekAlert | Comments

(Genome BC) Vancouver scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in...

TOPICS:

HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference

May 6, 2011 3:46 am | by Bio-Medicine.Org | Comments

FRAMINGHAM, Mass., and SYDNEY, May 6, 2011 /- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug...

TOPICS:

CDL MiniSense2 sales following Ocean Business

May 6, 2011 2:34 am | by I-Micronews | Comments

CDL sees an interest generated in the MiniSense2 system launched at this year?s Ocean Business conference in Southampton, UK, which has already translated into system sales.

Accuray Announces Results for Third Quarter of Fiscal 2011

May 6, 2011 2:33 am | by Bio-Medicine.Org | Comments

SUNNYVALE, Calif., May 5, 2011 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today financial results for the third quarter of fiscal year 2011, ended March 31, 2011. For the third quarter of fiscal 2011, Accuray reported total revenue of...

TOPICS:
Advertisement

Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death

May 6, 2011 1:33 am | by Boston Scientific | Comments

World's smallest and thinnest high-energy CRT-Ds and ICDs offer new features to optimize patient management

TOPICS:

Cardiac Network Announces Reverse Stock Split

May 6, 2011 12:35 am | by Bio-Medicine.Org | Comments

SAN FRANCISCO, May 5, 2011 /- Cardiac Network, Inc. (Other OTC: CNWI.PK) (the "Company") today announced that the Company will effect a 1-for-750 reverse stock split (the "Reverse Stock Split"). The Reverse Stock Split will take effect on the opening of business and trading on May 6, 2011...

TOPICS:

BD Launches BD MAXâ„¢ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians

May 6, 2011 12:35 am | by Bio-Medicine.Org | Comments

MILAN, May 6, 2011 /- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), today announced the European launch of the BD MAX™ Open System for molecular testing, which will enable laboratories to run both laboratory and BD- developed assays and offer enhanced...

TOPICS:

Annual General Meeting of Active Biotech AB(2)

May 5, 2011 10:46 pm | by The Associated Press | Comments

The Annual General Meeting of Active Biotech was held on May 5, 2011.In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.In accordance with the Election Committee's proposal, the Board members Mats Arnhog, Klas Karre, Magnhild Sandberg and Peter...

Annual General Meeting of Active Biotech AB

May 5, 2011 10:45 pm | Comments

The Annual General Meeting of Active Biotech was held on May 5, 2011.In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.In accordance with the Election Committee's proposal, the Board members Mats Arnhog, Klas Karre, Magnhild Sandberg and Peter...

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

May 5, 2011 5:35 pm | by Bio-Medicine.Org | Comments

EAST HANOVER, N.J., May 5, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients...

TOPICS:

PerkinElmer 1Q profit slips 4 percent(2)

May 5, 2011 4:46 pm | by The Associated Press | Comments

Health and industrial sciences company PerkinElmer Inc. said Thursday its profit fell 4 percent in the first quarter on charges related to businesses it has sold.PerkinElmer said its profit slipped to $23.5 million, or 20 cents per share, from $24.4 million, or 21 cents per share, a year ago....

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading